Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.627,33
0,22%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Editas Medicine Inc (EDIT) Editas Medicine Inc (EDIT) Notizie

EDIT

Editas Medicine (EDIT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EDIT
DataOraFonteTitoloSimboloCompagnia
31/05/202422:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EDITEditas Medicine Inc
31/05/202422:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
22/05/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
10/05/202412:00GlobeNewswire Inc.Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:EDITEditas Medicine Inc
08/05/202422:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EDITEditas Medicine Inc
08/05/202414:29IH Market NewsU.S. Futures Slightly Dip Amid Corporate Earnings and Quiet Economic Calendar, Oil Prices FallNASDAQ:EDITEditas Medicine Inc
08/05/202413:00GlobeNewswire Inc.Editas Medicine Announces First Quarter 2024 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
02/05/202413:00GlobeNewswire Inc.Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor EventsNASDAQ:EDITEditas Medicine Inc
01/05/202414:00GlobeNewswire Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationNASDAQ:EDITEditas Medicine Inc
22/04/202422:31GlobeNewswire Inc.Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:EDITEditas Medicine Inc
28/02/202423:13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:EDITEditas Medicine Inc
28/02/202422:39Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EDITEditas Medicine Inc
28/02/202413:00GlobeNewswire Inc.Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
21/02/202413:00GlobeNewswire Inc.Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor EventsNASDAQ:EDITEditas Medicine Inc
14/02/202414:40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EDITEditas Medicine Inc
31/01/202415:00GlobeNewswire Inc.Editas Medicine to Participate in Upcoming Investor ConferencesNASDAQ:EDITEditas Medicine Inc
08/01/202414:15GlobeNewswire Inc.Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare ConferenceNASDAQ:EDITEditas Medicine Inc
03/01/202413:00GlobeNewswire Inc.Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EDITEditas Medicine Inc
13/12/202318:48Dow Jones NewsEditas Medicine Strikes License Deal With Vertex Pharmaceuticals -- UpdateNASDAQ:EDITEditas Medicine Inc
13/12/202315:49Dow Jones NewsEditas Medicine Strikes License Deal With Vertex PharmaceuticalsNASDAQ:EDITEditas Medicine Inc
13/12/202315:00GlobeNewswire Inc.Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9NASDAQ:EDITEditas Medicine Inc
11/12/202318:00GlobeNewswire Inc.Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored WebinarNASDAQ:EDITEditas Medicine Inc
03/11/202312:00GlobeNewswire Inc.Editas Medicine Announces Third Quarter 2023 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
02/11/202314:12GlobeNewswire Inc.Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored WebinarNASDAQ:EDITEditas Medicine Inc
27/10/202313:00GlobeNewswire Inc.Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor EventsNASDAQ:EDITEditas Medicine Inc
16/10/202314:00GlobeNewswire Inc.Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell DiseaseNASDAQ:EDITEditas Medicine Inc
25/09/202322:30GlobeNewswire Inc.Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy OfficerNASDAQ:EDITEditas Medicine Inc
25/09/202315:00GlobeNewswire Inc.Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy OfficerNASDAQ:EDITEditas Medicine Inc
30/08/202315:00GlobeNewswire Inc.Editas Medicine Announces Upcoming Investor EventsNASDAQ:EDITEditas Medicine Inc
28/08/202313:00GlobeNewswire Inc.Medicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerNASDAQ:EDITEditas Medicine Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EDIT

La tua Cronologia

BIT
UC836F
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network